Phosphatbinder

Zhang QL, Rothenbacher D (2008) Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8:117 Couser WG, Remuzzi G, Mendis S, Tonelli M (2011) The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80:1258–1270 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease – mineral and bone disorder (CKD-MBD). Kidney Int Suppl 76(Suppl 113):S1–S130 Giachelli CM (2009) The emerging role of phosphate in vascular calcification. Kidney Int 75:890–897 Floege J, Kim J, Ireland E et al (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 26:1948−1955 Tentori F, Blayney MJ, Albert JM et al (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52:519−530 Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607−617 Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. JASN 15:2208−2218 Slinin Y, Foley RN, Collins AJ (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. JASN 16:1788−1793 Tonelli M, Pannu N, Manns B (2010) Oral phosphate binders in patients with kidney failure. N Engl J Med 362:1312−1324 Miyamoto K, Haito-Sugino S, Kuwahara S et al (2011) Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J Pharm Sci 100:3719−3730 Mizobuchi M, Towler D, Slatopolsky E (2009) Vascular calcification: the killer of patients with chronic kidney disease. JASN 20:1453−1464 Sigrist MK, Taal MW, Bungay P, McIntyre CW (2007) Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. CJASN 2:1241–1248 Block GA, Wheeler DC, Persky MS et al (2012) Effects of phosphate binders in moderate CKD. JASN 23:1407–1415 Russo D, Miranda I, Ruocco C et al (2007) The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72:1255–1261 KDOQI, National Kidney Foundation (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47(Suppl 3):S11–S145 Heng A-E, Cano NJM (2010) Nutritional problems in adult patients with stage 5 chronic kidney disease on dialysis (both haemodialysis and peritoneal dialysis). Nephrol Dial Transplant Plus 3:109–117, 118 Noori N, Kalantar-Zadeh K, Kovesdy CP et al (2010) Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. CJASN 5:683–692 Shinaberger CS, Greenland S, Kopple JD et al (2008) Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88:1511–1518 Lynch KE, Lynch R, Curhan GC, Brunelli SM (2011) Prescribed dietary phosphate restriction and survival among hemodialysis patients. CJASN 6:620–629 Sullivan C, Sayre SS, Leon JB et al (2009) Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 301:629–635 Isakova T, Gutiérrez OM, Chang Y et al (2009) Phosphorus binders and survival on hemodialysis. JASN 20:388–396 Cannata-Andia JB (2012) The use of phosphate binding agents is associated with lower mortality: results from the COSMOS study. 49th ERA-EDTA Congress, May 24–27, 2012, Paris Lopes AA, Tong L, Thumma J et al (2012) Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 60:90–101 Qunibi WY, Hootkins RE, McDowell LL et al (2004) Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:1914–1926 Brewster UC, Ciampi MA, Abu-Alfa AK, Reilly RF (2006) Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders. Nephrology (Carlton) 11:142–146 Jean G, Lataillade D, Genet L et al (2011) Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int 15:485–492 Goodman WG, Goldin J, Kuizon BD et al (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483 Francisco AL de, Leidig M, Covic AC et al (2010) Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 25:3707–3717 Wrong O, Harland C (2008) Sevelamer. Nephrol Dial Transplant 23:2108 De Santo NG, Frangiosa A, Anastasio P et al (2006) Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 19(Suppl 9):S108–S114 Delmez J, Block G, Robertson J et al (2007) A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 68:386–391 Pai AB, Shepler BM (2009) Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 29:554–561 Suki WN, Zabaneh R, Cangiano JL et al (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72:1130–1137 Di Iorio B, Bellasi A, Russo D; IDEPENDENT Study Investigators (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. CJASN 7:487–493 Block GA, Spiegel DM, Ehrlich J et al (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68:1815–1824 Braun J, Asmus HG, Holzer H et al (2004) Long-term comparison of a calcium-free phosphate binder and calcium carbonate – phosphorus metabolism and cardiovascular calcification. Clin Nephrol 62:104–115 Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252 Qunibi W, Moustafa M, Muenz LR et al (2008) A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51:952–965 Zhang Q, Li M, Lu Y et al (2010) Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 115:c259–c267 Brandenburg VM, Schlieper G, Heussen N et al (2010) Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 25:2672–2679 Finn WF, SPD 405–307 Lanthanum Study Group (2006) Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65:191–202 Sprague SM, Ross EA, Nath SD et al (2009) Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 72:252–258 Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A et al (2011) Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 26:2567–2571 D’Haese PC, Spasovski GB, Sikole A et al (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 85:S73–S78 Lacour B, Lucas A, Auchère D et al (2005) Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67:1062–1069 Hutchison AJ, Barnett ME, Krause R et al (2009) Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol 71:286–295 Karamanidou C, Clatworthy J, Weinman J, Horne R (2008) A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 9:2 Chiu YW, Teitelbaum I, Misra M et al (2009) Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. CJASN 4:1089–1096 Daugirdas JT, Chertow GM, Larive B et al (2012) Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. JASN 23:727–738 Cheng SC, Young DO, Huang Y et al (2008) A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. CJASN 3:1131–1138 Locatelli F, Dimkovic N, Pontoriero G et al (2010) Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant 25:574–581 Geisser P, Philipp E (2010) PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 74:4–11 Umanath K, Sika M, Niecestro R et al (2012) Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int [Epub ahead of print] Savica V, Calò LA, Monardo P et al (2009) Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. JASN 20:639–644